Associated Papers
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K et al.
Ebiomedicine, 2021
33862582 (PubMed )
Supplement: mmc3.xlsx › S5
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R et al.
Scientific Reports, 2020
33328484 (PubMed )
Supplement: 41598_2020_77939_MOESM1_ESM.xlsx › Sheet1
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
33173047 (PubMed )
Supplement: 41467_2020_19342_MOESM7_ESM.xlsx › PGI_fudan_NC_clnical.oc
Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.
Stoffel EM et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
30457921 (PubMed )
Supplement: ds_JCO.18.01489.pdf
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK et al.
Oncotarget, 2016
27588476 (PubMed )
Supplement: oncotarget-07-65364-s001.pdf
Genetic predisposition to pancreatic cancer.
Ghiorzo P
World Journal of Gastroenterology, 2014
Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
Harinck F et al.
Journal of Medical Genetics, 2012
Select a paper to view details